| Location: | Federal |
|---|---|
| Posted: | Feb 6, 2026 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Contract: | Awards |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | 75N91026P00004 |
| Publication URL: | To access bid details, please log in. |
This is a Firm Fixed Priced purchase order. NCI solicited and negotiated directly with Charles River Discovery Research Services UK Limited. The National Cancer Institute (NCI) has a program to use an antibody called, 'A10' to target cancer cells that have a lot of the epidermal growth factor receptor on their cell surface. While this antibody has been extensively tested and characterized it is not known if it also binds any other cell surface proteins. The contractor shall perform an off-target screen on an NCI antibody and report back on any problematic interactions that could predict a serious side effect should the antibody be given to a cancer patient. The A10 is NOT known to bind other cell surface proteins or secreted proteins but this needs to be addressed in the off-target screen.

With GovernmentContracts, you can:
...Follow CNC Plasma Arc Cutting Machine Active Contract Opportunity Notice ID W911KF26QA037 Related... ...
DEPT OF DEFENSE
Bid Due: 6/10/2026
...Follow TECHNOLOGY TRANSFER LICENSING OPPORTUNITY: Plasma Processing of Water and Inedible Biomass...: Researchers ...
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
Bid Due: 7/17/2026
...analysis in plasma samples Attachments/Links Contact Information Contracting Office Address 6011...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 6/07/2026
...-based untargeted omics tools to identify blood metabolites, circulating plasma proteins, and global...
VETERANS AFFAIRS, DEPARTMENT OF
Bid Due: 6/05/2026